Gilead Reports real-world evidence Data for Alirocumab in Atopic dermatitis

Gilead today announced real-world evidence results for alirocumab in patients with atopic dermatitis. The study demonstrated that alirocumab achieves complete response compared to standard of care or placebo. These results provide important insights into the treatment of atopic dermatitis and support the continued development of alirocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.